Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis

Stopped early · Early Phase 1 · Has a placebo group

Conditions studied: Clinical High Risk for Psychosis

In brief

The primary objective of this study is to determine whether aspirin is effective in alleviating symptoms of the clinical high risk (CHR) syndrome for psychosis. The investigators further aim to determine whether it may delay or prevent the onset of psychosis in those currently experiencing CHR symptoms. As secondary measures the investigators aim to collect laboratory studies of inflammation markers and genetic samples to determine whether certain genetic profiles correlate with risk for psychosis, or response to aspirin treatment.

Key facts

Study ID
NCT02047539
Run by
Yale University
People needed
1
Starts
2015-01-01
Expected to finish
2021-03-01
Last updated by the study team
2021-05-17

Who can join

Age: 19 and older, up to 35. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.